静脉畸形合并局限性血管内凝血研究进展

doi:10.19438/j.cjoms.2026.01.014

摘要/Abstract

摘要： 静脉畸形（venous malformations,VMs）是一种先天性低流速血管畸形,常伴有消耗性凝血功能障碍,以D二聚体升高、纤维蛋白原降低为特征性改变,称为局限性血管内凝血（localized intravascular coagulation,LIC）。LIC患者可表现为患处肿胀及疼痛,在少数情况下,可能导致严重的出凝血并发症,如弥散性血管内凝血。本文就VMs伴发LIC的病理生理学机制、临床表现、实验室检查、诊断和治疗等作一全面综述,旨在为临床医师处理该类患者提供参考。

关键词: 静脉畸形, 凝血功能障碍, 局限性血管内凝血, D二聚体, 纤维蛋白原

Abstract: Venous malformations(VMs) are congenital low-flow vascular anomalies associated with consumptive coagulopathy, characterized by elevated D-dimer and decreased fibrinogen levels, termed localized intravascular coagulation (LIC). Patients with LIC may present with localized swelling and pain. In rare cases, LIC can progress to severe coagulopathic complications, such as disseminated intravascular coagulation(DIC). This article provided a comprehensive review of the pathophysiology, clinical manifestations, laboratory findings, diagnosis, and treatment of VMs complicated by LIC, aiming to support clinical decision-making in this patient population.

Key words: Venous malformation, Coagulopathy, Localized intravascular coagulation, D-dimer, Fibrinogen

中图分类号:

王紫璐, 王德明, 苏立新, 范新东. 静脉畸形合并局限性血管内凝血研究进展[J]. 中国口腔颌面外科杂志, 2026, 24(1): 89-95.

Wang Zilu, Wang deming, Su lixin, Fan Xindong. Advances in the study of venous malformations complicated with localized intravascular coagulation[J]. China J Oral Maxillofac Surg, 2026, 24(1): 89-95.

参考文献

[1] Legiehn GM, Heran MKS.Venous malformations: classification, development, diagnosis, and interventional radiologic management[J]. Radiol Clin North Am, 2008, 46(3): 545-597.
[2] Limaye N, Wouters V, Uebelhoer M, et al.Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations[J]. Nat Genet, 2009, 41(1): 118-124.
[3] Soblet J, Kangas J, Nätynki M, et al.Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017, 137(1): 207-216.
[4] Limaye N, Kangas J, Mendola A, et al.Somatic activating PIK3CA mutations cause venous malformation[J]. Am J Hum Genet, 2015, 97(6): 914-921.
[5] Wouters V, Limaye N, Uebelhoer M, et al.Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects[J]. Eur J Hum Genet, 2010, 18(4): 414-420.
[6] Garzon MC, Huang JT, Enjolras O, et al.Vascular malformations. part I[J]. J Am Acad Dermatol, 2007, 56(3): 353-370.
[7] Eivazi B, Fasunla AJ, Güldner C, et al.Phleboliths from venous malformations of the head and neck[J]. Phlebology, 2013, 28(2): 86-92.
[8] Hein KD, Mulliken JB, Kozakewich HPW, et al.Venous malformations of skeletal muscle[J]. Plast Reconstr Surg, 2002, 110(7): 1625-1635.
[9] Kasabach HH, Merritt KK.Capillary hemangioma with extensive purpura: report of a case[J]. Am J Dis Child, 1940, 59(5): 1063-1070.
[10] Mulliken JB, Glowacki J.Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics[J]. Plast Reconstr Surg, 1982, 69(3): 412-422.
[11] Mazoyer E, Enjolras O, Laurian C, et al.Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome[J]. Clin Lab Haematol, 2002, 24(4): 243-251.
[12] Kelly M.Kasabach-Merritt phenomenon[J]. Pediatr Clin North Am, 2010, 57(5): 1085-1089.
[13] Han YY, Sun LM, Yuan SM.Localized intravascular coagulation in venous malformations: a system review[J]. Phlebology, 2021, 36(1): 38-42.
[14] Mazoyer E, Enjolras O, Bisdorff A, et al.Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients[J]. Arch Dermatol, 2008, 144(7): 861-867.
[15] Dompmartin A, Acher A, Thibon P, et al.Association of localized intravascular coagulopathy with venous malformations[J]. Arch Dermatol, 2008, 144(7): 873-877.
[16] Van Es J, Kappelhof NA, Douma RA, et al.Venous thrombosis and coagulation parameters in patients with pure venous malformations[J]. Neth J Med, 2017, 75(8): 328-334.
[17] Aronniemi J, Långström S, Mattila KA, et al.Venous malformations and blood coagulation in children[J]. Children, 2021, 8(4): 312-320.
[18] Swerdlin RF, Briones MA, Gill AE, et al.Coagulopathy and related complications following sclerotherapy of congenital venous malformations[J]. Pediatr Blood Cancer, 2022, 69(5): e29610.
[19] 邰茂众, 秦中平, 郑家伟, 等. 局限性血管内凝血诊断与治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(4): 313-321.
Tai MZ, Qin ZP, Zheng JW, et al.Chinese expert consensus on diagnosis and treatment of localized intravascular coagulopathy[J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 313-321.
[20] Hung JWS, Leung MWY, Liu CSW, et al.Venous malformation and localized intravascular coagulopathy in children[J]. Eur J Pediatr Surg, 2017, 27(2): 181-184.
[21] 邝新捷. 静脉畸形合并局限性血管内凝血的相关因素分析[D]. 开封:河南大学,2024.
Kuang XJ.Analysis of related factors of venous malformations combined with localized intravascular coagulation[D]. Kaifeng: Henan University, 2024.
[22] Vikkula M, Boon LM, Carraway KL, et al.Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2[J]. Cell, 1996, 87(7): 1181-1190.
[23] Redondo P, Aguado L, Marquina M, et al.Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: implications for antiangiogenic/antithrombotic strategies[J]. Br J Dermatol, 2010, 162(2): 350-356.
[24] Nava Y Hurtado F, Monzon Manzano E, Viana-Huete V, et al. Assessing coagulopathy and endothelial dysfunction in pediatric venous malformation: a thromboelastometry and syndecan-1 study[J]. Pediatr Blood Cancer, 2024, 71(5): e30915.
[25] Adams DM.Special considerations in vascular anomalies: hematologic management[J]. Clin Plast Surg, 2011, 38(1): 153-160.
[26] Nätynki M, Kangas J, Miinalainen I, et al.Common and specific effects of TIE2 mutations causing venous malformations[J]. Hum Mol Genet, 2015, 24(22): 6374-6389.
[27] Li Y, Yang J, Huang Y, et al.Cellular heterogeneity and immune microenvironment revealed by single-cell transcriptome in venous malformation and cavernous venous malformation[J]. J Mol Cell Cardiol, 2022, 162: 130-143.
[28] Mazereeuw-Hautier J, Syed S, Leisner RI, et al.Extensive venous/lymphatic malformations causing life-threatening haematological complications[J]. Br J Dermatol, 2007, 157(3): 558-563.
[29] Oduber CEU, Gerdes VEA, Van der Horst CMAM, et al. Vascular malformations as underlying cause of chronic thromboembolism and pulmonary hypertension[J]. J Plast Reconstr Aesthetic Surg, 2009, 62(5): 684-689.
[30] Chun HJ, Osuga K, Ukai I, et al.Spontaneous splenic rupture due to extensive venous malformation with consumptive coagulopathy: treatment with splenic artery embolization[J]. Jpn J Radiol, 2010, 28(5): 381-384.
[31] Dompmartin A, Ballieux F, Thibon P, et al.Elevated D-dimer level in the differential diagnosis of venous malformations[J]. Arch Dermatol, 2009, 145(11): 1239-1244.
[32] 韩钰钰, 余明薇, 王慜, 等. 体表软组织静脉畸形中局限性血管内凝血的临床特征分析[J]. 组织工程与重建外科, 2022, 18(3): 214-219.
Han YY, Yu MW, Wang M, et al.Clinical features of localized intravascular coagulation in venous malformations[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2022, 18(3): 214-219.
[33] Ruggeri ZM.The role of von Willebrand factor in thrombus formation[J]. Thromb Res, 2007, 120(Suppl 1): S5-S9.
[34] Kapp FG, Schneider C, Holm A, et al.Comprehensive analyses of coagulation parameters in patients with vascular anomalies[J]. Biomolecules, 2022, 12(12): 1840.
[35] Nissen IT, Hedelund L, Larsen JB, et al.Thrombophilia in patients with venous malformations[J]. Thromb Res, 2022, 212: 1-3.
[36] Zheng M, Zhong HY, Sun YR, et al.A long-term follow-up study of the changes in localized intravascular coagulation-related indexes after sclerotherapy of venous malformation[J]. Phlebology, 2025, 40(5): 345-352.
[37] Yu MW, Han YY, Wang Q, et al.Treatment outcomes and effects of ethanol sclerotherapy on systemic coagulation profile of patients with venous malformation[J]. Ann Vasc Surg, 2022, 85: 268-275.
[38] 康佳佳. 凝血指标在儿童静脉畸形硬化治疗中的临床意义 [D]. 重庆: 重庆医科大学, 2024.
Kang JJ.Clinical significance of coagulation indicators in sclerotherapy for venous malformations in children [D]. Chongqing: Chongqing Medical University, 2024.
[39] Adams DM, Trenor CC, Hammill AM, et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016, 137(2): e20153257.
[40] Blesinger H, Kaulfuß S, Aung T, et al.PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J]. PLoS One, 2018, 13(7): e0200343.
[41] Hammill AM, Wentzel M, Gupta A, et al.Sirolimus for the treatment of complicated vascular anomalies in children[J]. Pediatr Blood Cancer, 2011, 57(6):1018-1024.
[42] Zabeida A, Brzezinski JJ, Wasserman JD, et al.Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome[J]. Pediatr Blood Cancer, 2024, 71(11): e31282.
[43] Maruani A, Tavernier E, Boccara O, et al.Sirolimus (Rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial[J]. JAMA Dermatol, 2021, 157(11): 1289-1298.
[44] Maillet C, Boccara O, Mallet S, et al.Long-term effects of sirolimus treatment for slow-flow vascular malformations: real-world evidence from the French observational multicentre SIROLO study[J]. J Eur Acad Dermatol Venereol, 2024, 39(5): 1046-1054.
[45] Mack JM, Verkamp B, Richter GT, et al.Effect of sirolimus on coagulopathy of slow-flow vascular malformations[J]. Pediatr Blood Cancer, 2019, 66(10): e27896.
[46] Venot Q, Blanc T, Rabia SH, et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018, 558(7711): 540-546.
[47] Remy A, Tran TH, Dubois J, et al.Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: preliminary pharmacokinetics and pharmacodynamic data[J]. Pediatr Blood Cancer, 2022, 69(10): e29897.
[48] Delestre F, Venot Q, Bayard C, et al. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients[J]. Sci Transl Med, 2021, 13(614): eabg0809.
[49] Canaud G, Lopez Gutierrez JC, Irvine AD, et al.Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)[J]. Genet Med, 2023, 25(12): 100969.
[50] Zerbib L, Ladraa S, Fraissenon A, et al.Targeted therapy for capillary-venous malformations[J]. Signal Transduct Target Ther, 2024, 9(1): 146-161.
[51] Sterba M, Pokorna P, Faberova R, et al.Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity[J]. Sci Rep, 2023, 13(1): 10499.
[52] Langbroek GB, Horbach SER, Van der Vleuten CJM, et al. Compression therapy for congenital low-flow vascular malformations of the extremities: a systematic review[J]. Phlebology, 2018, 33(1): 5-13.
[53] Enjolras O, Ciabrini D, Mazoyer E, et al.Extensive pure venous malformations in the upper or lower limb: a review of 27 cases[J]. J Am Acad Dermatol, 1997, 36(2 Pt 1): 219-225.
[54] Ricci KW, Brandão LR.Coagulation issues in vascular anomalies[J]. Semin Pediatr Surg, 2020, 29(5): 150966.
[55] Ricci KW, Chute C, Hammill AM, et al.Retrospective study of hematologic complications in patients with slow-flow vascular malformations undergoing sclerotherapy[J]. Pediatr Blood Cancer, 2020, 67(10): e28277.
[56] Serrano F, Bisdorff-Bresson A, Sroussi J, et al.Giant intrahepatic venous malformation with localized intravascular coagulopathy. follow-up and treatment during pregnancy[J]. J Med Vasc, 2020, 45(6): 309-315.
[57] Lagneaux E, Boon LM, Revencu N, et al.Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients[J]. Res Pract Thromb Haemost, 2024, 8(3): 102400.
[58] Vandenbriele C, Vanassche T, Peetermans M, et al.Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation[J]. J Thromb Thrombolysis, 2014, 38(1): 121-123.
[59] Binet Q, Lambert C, Hermans C.Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations[J]. Thromb Res, 2018, 168: 114-120.
[60] Yasumoto A, Ishiura R, Narushima M, et al.Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations[J]. Blood Coagul Fibrinolysis, 2017, 28(8): 670-674.
[61] Ardillon L, Lambert C, Eeckhoudt S, et al.Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations[J]. Blood Coagul Fibrinolysis, 2016, 27(2): 216-219.
[62] Liu H, Hu L, Yang X, et al. Dabigatran etexilate is efficacious in consumptive coagulopathy and pain associated with venous malformations[J]. J Vasc Surg Venous Lymphat Disord, 2023, 11(2): 397-403.e1.
[63] Ali B, Panossian A, Taghinia A, et al.Diffuse venous malformations of the upper extremity (bockenheimer disease): diagnosis and management[J]. Plast Reconstr Surg, 2020, 146(6): 1317-1324.
[64] Nguyen JT, Koerper MA, Hess CP, et al.Aspirin therapy in venous malformation: a retrospective cohort study of benefits, side effects, and patient experiences[J]. Pediatr Dermatol, 2014, 31(5): 556-560.